{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:51:05Z","timestamp":1791773465679,"version":"4.3.4"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n Clinician-reported and patient-reported outcomes are critical measures of therapeutic efficacy in cutaneous chronic graft-vs-host disease (cGVHD) but are not always correlated. Discordance in treatment response between clinicians and patients hinders interpretation of outcomes in clinical trials and complicates therapeutic decision-making in clinical practice.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To identify factors associated with discordance in clinician-reported and patient-reported treatment response assessments and to evaluate the association of clinician-reported and patient-reported responses with survival.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter longitudinal cohort study included adults 18 years and older with cutaneous cGVHD at study enrollment, assembled from 2 observational studies and 1 randomized clinical trial. Data were collected from August 2007 to March 2024, and data were analyzed from July 2024 to May 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n A global 8-point cutaneous cGVHD treatment response assessment (with 1 indicating resolved and 8 indicating very much worse) was reported by clinicians and patients 3 to 6 months after study enrollment. Clinician-reported and patient-reported treatment responses were categorized into improved, stable, and worse from the 8-point scale, and discordance was defined as a difference in response between clinicians and patients. Positive clinician discordance indicates the clinician reported a better response than the patient, and negative clinician discordance indicates the clinician reported a worse response than the patient. The association of clinician-reported and patient-reported responses with survival was measured by nonrelapse mortality.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 489 adults with cutaneous cGVHD, 192 (39.3%) were female, 297 (60.7%) were male, and the median (IQR) age was 55 (43-62) years. A total of 321 adults (65.6%) had concordant responses and 168 (34.4%) had discordant responses between clinician-reported and patient-reported treatment responses. Patients with sclerotic cGVHD had greater odds of discordance compared with those without sclerosis, with clinicians reporting both better and worse treatment response than patients (positive clinician discordance: adjusted odds ratio, 3.14; 95% CI, 1.41-6.95;\n P<\/jats:italic>\n \u2009=\u2009.005; negative clinician discordance: adjusted odds ratio, 2.33; 95% CI, 1.19-4.56;\n P<\/jats:italic>\n \u2009=\u2009.01). Worsening compared with improved overall cutaneous cGVHD was associated with nonrelapse mortality when reported by clinicians (adjusted hazard ratio, 2.28; 95% CI, 1.46-3.54;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and patients (adjusted hazard ratio, 1.86; 95% CI, 1.12-3.08;\n P<\/jats:italic>\n \u2009=\u2009.02), while only patient-reported worsening was significantly associated with nonrelapse mortality in patients with sclerotic disease (adjusted hazard ratio, 2.00; 95% CI, 1.02-3.90;\n P<\/jats:italic>\n \u2009=\u2009.04).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, discordance in treatment response assessments between clinicians and patients was common in cutaneous cGVHD, yet clinician-reported and patient-reported treatment responses were both associated with survival. In patients with sclerosis who were more likely to experience discordance, patient-reported response was a critical treatment end point, and approaches should be developed to bridge discordance.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.5545","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:33Z","timestamp":1769011233000},"page":"245","source":"Crossref","is-referenced-by-count":3,"title":["Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease"],"prefix":"10.1001","volume":"162","author":[{"given":"Varshini","family":"Babu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Onstad","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Pidala","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Chen","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation & Cellular Therapy Department, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Cutler","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[{"name":"Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Baumrin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"doi250067r1","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1182\/bloodadvances.2024012722","article-title":"Decreasing chronic graft-versus-host disease rates in all populations.","volume":"8","author":"Carpenter","year":"2024","journal-title":"Blood Adv"},{"issue":"25","key":"doi250067r2","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis.","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"doi250067r3","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"doi250067r4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation.","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"},{"issue":"16","key":"doi250067r5","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"doi250067r6","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"9","key":"doi250067r7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia.","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"3","key":"doi250067r8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of immunosuppressive treatments in patients with chronic graft-versus-host disease.","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"doi250067r9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease.","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"doi250067r10","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study.","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"doi250067r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2023-186963","article-title":"Safety and efficacy of axatilimab at 3 different doses in patients with chronic graft-versus-host disease (AGAVE-201).","volume":"142","author":"Wolff","year":"2023","journal-title":"Blood"},{"issue":"13","key":"doi250067r12","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1182\/blood-2012-04-424135","article-title":"Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.","volume":"120","author":"Jacobsohn","year":"2012","journal-title":"Blood"},{"issue":"10","key":"doi250067r13","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease.","volume":"23","author":"Kurosawa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"doi250067r14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbmt.2019.10.019","article-title":"Disability related to chronic graft-versus-host disease.","volume":"26","author":"Hamilton","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"doi250067r15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2022.6624","article-title":"Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease.","volume":"159","author":"Baumrin","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi250067r16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bmt.2014.188","article-title":"NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.","volume":"49","author":"Curtis","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"doi250067r17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. the 2014 Response Criteria Working Group report.","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"doi250067r18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","article-title":"Reliability and validity of the modified 7-day Lee Chronic Graft-versus-Host Disease Symptom Scale.","volume":"26","author":"Teh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"doi250067r19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2023.6277","article-title":"Patient-reported outcomes and mortality in cutaneous chronic graft-vs-host disease.","volume":"160","author":"Baumrin","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi250067r20","first-page":"143","article-title":"Patient-reported treatment response in chronic graft-versus-host disease.","volume":"109","author":"Im","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"doi250067r21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2133.2001.04445.x","article-title":"Factors associated with patient satisfaction with care among dermatological outpatients.","volume":"145","author":"Renzi","year":"2001","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi250067r22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000551","article-title":"Discordant patient-physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis.","volume":"3","author":"Karpouzas","year":"2017","journal-title":"RMD Open"},{"issue":"2","key":"doi250067r23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/1078-0432.CCR-15-1443","article-title":"A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation.","volume":"22","author":"Arai","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"doi250067r24","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.bbmt.2018.02.010","article-title":"Design and patient characteristics of the chronic graft-versus-host disease response measures validation study.","volume":"24","author":"Chronic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"doi250067r25","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.bbmt.2011.05.007","article-title":"Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.","volume":"17","author":"Chronic GVHD Consortium","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"doi250067r26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report.","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"doi250067r27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 Diagnosis and Staging Working Group report.","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"doi250067r28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr.22401","article-title":"Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients.","volume":"67","author":"Eder","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"doi250067r29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40257-017-0284-y","article-title":"Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey.","volume":"18","author":"Wei","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"doi250067r30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1468-3083.2011.04038.x","article-title":"Disease severity evaluation among dermatological out-patients: a comparison between the assessments of patients and physicians.","volume":"26","author":"Tabolli","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi250067r31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamadermatol.2023.2008","article-title":"Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling.","volume":"159","author":"Long","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi250067r32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/bmt.2009.84","article-title":"Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD.","volume":"44","author":"Jacobsohn","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"doi250067r34","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1182\/blood-2011-04-350249","article-title":"Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.","volume":"118","author":"Martires","year":"2011","journal-title":"Blood"},{"issue":"10","key":"doi250067r35","doi-asserted-by":"publisher","first-page":"700.e1","DOI":"10.1016\/j.jtct.2022.06.020","article-title":"Correlation of patient-reported outcomes with clinical organ responses: data from the Belumosudil Chronic Graft-Versus-Host Disease studies.","volume":"28","author":"Lee","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"doi250067r36","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jamadermatol.2018.5459","article-title":"Interrater reliability of clinical grading measures for cutaneous chronic graft-vs-host disease.","volume":"155","author":"Cardones","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250067r37","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2214\/AJR.08.1699","article-title":"Musculocutaneous chronic graft-versus-host disease: MRI follow-up of patients undergoing immunosuppressive therapy.","volume":"192","author":"Horger","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"9","key":"doi250067r38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jtct.2021.05.030","article-title":"Methods to assess disease activity and severity in cutaneous chronic graft-versus-host disease: a critical literature review.","volume":"27","author":"Shakshouk","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"doi250067r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100246","article-title":"Identification of fibroinflammatory and fibrotic transcriptomic subsets of human cutaneous sclerotic chronic graft-versus-host disease.","volume":"4","author":"Rosenstein","year":"2023","journal-title":"JID Innov"},{"issue":"9","key":"doi250067r40","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","article-title":"Patient-reported outcomes and health status associated with chronic graft-versus-host disease.","volume":"103","author":"Lee","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"doi250067r41","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/blood.2024027334","article-title":"Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis.","volume":"145","author":"Baumrin","year":"2025","journal-title":"Blood"},{"key":"doi250067r33","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harrell","year":"2001"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2844108\/jamadermatology_babu_2026_oi_250067_1772642726.70325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:00:27Z","timestamp":1773846027000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2844108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.5545","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}